Hendra Virus and Nipah Virus Therapy and Vaccine

Date/Time: 10 October 2017, 10:15 AM
Speaker: Christopher C. Broder, Ph.D.
Speaker Affiliation: Professor and Graduate Program Director, Department of Microbiology and Immunology Uniformed Services, University of the Health Sciences, Bethesda,Maryland
Venue: John A. Burns School of Medicine, Medical Education Building Auditorium (Room 315)

For more info: Cori Watanabe 808 692-1654
Description: Hendra virus (HeV) and Nipah virus (NiV) are highly pathogenic bat-borne paramyxoviruses, which emerged in the 1990s causing disease outbreaks in livestock and people, are important trans-boundary biological threats. HeV appeared in Australia and since 1994 there have been 59 spillover events and more than 100 horse deaths, and 4 of 7 human case fatalities. NiV first appeared in Malaysia and subsequent outbreaks have occurred in Bangladesh and India, totaling >600 human cases with fatality rates from 40% to 100%. A human monoclonal antibody targeting the viral G glycoprotein has been shown to be an effective post-exposure treatment against HeV and NiV in animals and has been used in 15 individuals by emergency protocol. A subunit vaccine based on the HeV G glycoprotein can provide complete protection against HeV or NiV infection in several animal models, and a vaccine (Equivac HeV) is now available in Australia to protect horses from HeV infection.
Additional Document:Click here to download